NCT01969721View on ClinicalTrials.gov

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

229

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

fluticasone propionate

low dose

DRUG

salmeterol

DRUG

placebo

placebo/dummy for blinding purposes

DRUG

placebo

placebo/dummy for blinding purposes

DRUG

tiotropium

tiotropium high dose

DRUG

olodaterol

DRUG

olodaterol

DRUG

placebo

placebo/dummy for blinding purposes

DRUG

placebo

placebo/dummy for blinding purposes

DRUG

tiotropium

tiotropium low dose

DRUG

fluticasone propionate

low dose

DRUG

salmeterol

Trial Locations (29)

Unknown

1237.11.32002 Boehringer Ingelheim Investigational Site, Genk

1237.11.32001 Boehringer Ingelheim Investigational Site, Ghent

1237.11.42003 Boehringer Ingelheim Investigational Site, Kyjov

1237.11.42004 Boehringer Ingelheim Investigational Site, Rokycany

1237.11.42002 Boehringer Ingelheim Investigational Site, Tábor

1237.11.42001 Boehringer Ingelheim Investigational Site, Třebíč

1237.11.45002 Boehringer Ingelheim Investigational Site, Hvidovre

1237.11.45004 Boehringer Ingelheim Investigational Site, Kolding

1237.11.45001 Boehringer Ingelheim Investigational Site, Odense C

1237.11.45003 Boehringer Ingelheim Investigational Site, Silkeborg

1237.11.49003 Boehringer Ingelheim Investigational Site, Großhansdorf

1237.11.49005 Boehringer Ingelheim Investigational Site, Hamburg

1237.11.49001 Boehringer Ingelheim Investigational Site, Mannheim

1237.11.49004 Boehringer Ingelheim Investigational Site, Mönchengladbach

1237.11.49002 Boehringer Ingelheim Investigational Site, Wiesbaden

1237.11.36001 Boehringer Ingelheim Investigational Site, Debrecen

1237.11.36004 Boehringer Ingelheim Investigational Site, Pécs

1237.11.36003 Boehringer Ingelheim Investigational Site, Szeged

1237.11.36002 Boehringer Ingelheim Investigational Site, Szombathely

1237.11.31005 Boehringer Ingelheim Investigational Site, Almelo

1237.11.31002 Boehringer Ingelheim Investigational Site, Breda

1237.11.31006 Boehringer Ingelheim Investigational Site, Eindhoven

1237.11.31001 Boehringer Ingelheim Investigational Site, Heerlen

1237.11.31007 Boehringer Ingelheim Investigational Site, Hoorn

1237.11.31003 Boehringer Ingelheim Investigational Site, Zutphen

1237.11.34003 Boehringer Ingelheim Investigational Site, Alicante

1237.11.34001 Boehringer Ingelheim Investigational Site, Barcelona

1237.11.34002 Boehringer Ingelheim Investigational Site, Pozuelo de Alarcón

1237.11.46001 Boehringer Ingelheim Investigational Site, Lund

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01969721 - Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients | Biotech Hunter | Biotech Hunter